These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 16977635

  • 1. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM, Wang XH, Aswald S, Lutynski A, Minden MD, Messner HA, Keating A.
    Cytometry B Clin Cytom; 2006 Nov 15; 70(6):379-90. PubMed ID: 16977635
    [Abstract] [Full Text] [Related]

  • 2. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
    Wongprajun S, Auewarakul CU.
    J Med Assoc Thai; 2010 Jan 15; 93 Suppl 1():S157-64. PubMed ID: 20364570
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, Rolinski J, Hus I, Dmoszynska A, Wiesneth M, Schmitt M.
    Int J Oncol; 2006 Apr 15; 28(4):855-61. PubMed ID: 16525634
    [Abstract] [Full Text] [Related]

  • 4. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
    Drach J, Drach D, Glassl H, Gattringer C, Huber H.
    Cytometry; 1992 Apr 15; 13(8):893-901. PubMed ID: 1459006
    [Abstract] [Full Text] [Related]

  • 5. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, Shiraishi K, Nakagawa K, Kakimi K.
    Cytotherapy; 2008 Apr 15; 10(8):842-56. PubMed ID: 19016372
    [Abstract] [Full Text] [Related]

  • 6. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N, Narita M, Yokoyama A, Sekiguchi A, Saito A, Tochiki N, Furukawa T, Toba K, Aizawa Y, Takahashi M.
    Cytotherapy; 2006 Apr 15; 8(2):118-29. PubMed ID: 16698685
    [Abstract] [Full Text] [Related]

  • 7. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
    Zhong RK, Lane TA, Ball ED.
    Exp Hematol; 2008 Apr 15; 36(4):486-94. PubMed ID: 18249062
    [Abstract] [Full Text] [Related]

  • 8. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A, Charbonnier A, Collette Y, Vey N, Olive D.
    J Immunol; 2012 May 01; 188(9):4701-8. PubMed ID: 22467661
    [Abstract] [Full Text] [Related]

  • 9. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
    Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, Lamb LS.
    Bone Marrow Transplant; 2007 Jun 01; 39(12):751-7. PubMed ID: 17450185
    [Abstract] [Full Text] [Related]

  • 10. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
    Torelli GF, Guarini A, Maggio R, Alfieri C, Vitale A, Foà R.
    Haematologica; 2005 Jun 01; 90(6):785-92. PubMed ID: 15951291
    [Abstract] [Full Text] [Related]

  • 11. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.
    Braza MS, Caraux A, Rousset T, Lafaye de Micheaux S, Sicard H, Squiban P, Costes V, Klein B, Rossi JF.
    J Immunol; 2010 Jan 01; 184(1):134-40. PubMed ID: 19949101
    [Abstract] [Full Text] [Related]

  • 12. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, Meflah K, Gregoire M.
    Cancer Res; 2002 May 15; 62(10):2861-8. PubMed ID: 12019165
    [Abstract] [Full Text] [Related]

  • 13. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T, Babusíková O.
    Neoplasma; 2006 May 15; 53(6):500-6. PubMed ID: 17167719
    [Abstract] [Full Text] [Related]

  • 14. Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia.
    Park HH, Kim M, Lee BH, Lim J, Kim Y, Lee EJ, Min WS, Kang CS, Kim WI, Shim SI, Han K.
    Ann Clin Lab Sci; 2006 May 15; 36(1):7-15. PubMed ID: 16501231
    [Abstract] [Full Text] [Related]

  • 15. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
    Gaafar A, Aljurf MD, Al-Sulaiman A, Iqniebi A, Manogaran PS, Mohamed GE, Al-Sayed A, Alzahrani H, Alsharif F, Mohareb F, Ajarim D, Tabakhi A, Al-Hussein K.
    Exp Hematol; 2009 Jul 15; 37(7):838-48. PubMed ID: 19446661
    [Abstract] [Full Text] [Related]

  • 16. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
    Murayama M, Tanaka Y, Yagi J, Uchiyama T, Ogawa K.
    Anticancer Res; 2008 Jul 15; 28(5B):2921-31. PubMed ID: 19031935
    [Abstract] [Full Text] [Related]

  • 17. Circulating TCR gammadelta cells in the patients with systemic lupus erythematosus.
    Robak E, Błoński JZ, Bartkowiak J, Niewiadomska H, Sysa-Jedrzejowska A, Robak T.
    Mediators Inflamm; 1999 Jul 15; 8(6):305-12. PubMed ID: 10815619
    [Abstract] [Full Text] [Related]

  • 18. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH, Kang HK, Park JS, Kim SK, Pham TN, Zhu XW, Cho D, Nam JH, Chung IJ, Kim YJ, Rhee JH, Kim HJ, Lee JJ.
    J Clin Apher; 2006 Dec 15; 21(4):233-40. PubMed ID: 17120232
    [Abstract] [Full Text] [Related]

  • 19. [Detection of minimal residual disease in patients with acute myeloid leukemia].
    Gal'tseva IV, Savchenko VG, Kulikov SM, Parovichnikova EN, Miterev GIu, Maslova ER, Isaev VG.
    Ter Arkh; 2003 Dec 15; 75(7):8-14. PubMed ID: 12934474
    [Abstract] [Full Text] [Related]

  • 20. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
    Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T.
    Haematologica; 2004 May 15; 89(5):528-40. PubMed ID: 15136215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.